Nuclear magnetic resonance –based co-magnetometers are essential tools for applications ranging from inertial navigation to geophysical exploration and biomedical sensing. Their performance critically ...

Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational ...

NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a ...

The trial aims to assess the tolerability, safety, efficacy, functional outcomes, and dystrophin expression in affected patients.

Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division. This was supported by lab experiments showing that lowering deuterium levels ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Chowning is a composer, musician and professor that had a seismic impact on both the development of music technology and the ...

LCGC International salutes Jack Henion and Bob W.J. Pirok, winners of the 19th annual LCGC Lifetime Achievement and Emerging ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...